No Data
CANbridge Pharma Terminates Lease in Massachusetts Amid US Downsizing Efforts
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
North Sea Kang Cheng - B [01228] is currently reported at HKD 0.148, with an increase of 19.36%.
As of 11:57, Beihai Kangcheng - B [01228] is priced at 0.148 Hong Kong dollars, an increase of 0.024 Hong Kong dollars or 19.36% compared to yesterday's closing price of 0.124 Hong Kong dollars, with a trading volume of 0.0222 million Hong Kong dollars. Today's highest price is 0.148 Hong Kong dollars, and the lowest price is 0.132 Hong Kong dollars. Based on yesterday's closing price, the 10-day average price is 0.12 Hong Kong dollars, the 50-day average price is 0.15 Hong Kong dollars, and the current PE is -0.13 times, with a 14-day strength index of 42.98.
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 25% Dip In Price Shows Sentiment Is Matching Revenues
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Beihai Kangcheng announced that Mai Ruibei for the treatment of PFIC cholestatic pruritus has been approved for sale in Taiwan.
